Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Double vaccine against Human Immunodeficient virus

23.07.2007
A vaccine against HIV infections is the most reliable way to stop the AIDS epidemic. A lot of researchers in various countries have been working for more than 20 years to cope with this task. However, the vaccine development is complicated by the fact that human immunodeficiency virus is very changeable, it is able to “hide” from the immune system and causes heavy immunopathologies.

The Novosibirsk researchers have developed a vaccine that is able to cause both humoral and cellular immunity, it means that under the influence of this vaccine, activated cells of the immune system will both form virus antibodies and devour the cells infected by the virus.

The vaccine per se is an artificial virus-like particle. Its capsule consists of the TBI (T- and B cell epitopes containing immunogen) protein constructed by the researchers, the TBI protein being combined with the polyglucin protein. This protein contains 9 participants stimulating different cells of the immune system – both the ones that produce antibodies and the ones that devour the newcomer. The DNA coding the TCI (T-cell immunogen) protein is contained inside the protein coat. The protein contains more than 80 HIV proteins fragments selected in the optimal way, which should activate the immune system.

The researchers have selected only conservative fragments, i.e. the ones that remain constant in the course of all major changes of HIV-1 and will certainly be noticed by the immunize organism. As a matter of fact, the coat and the filling of the particle represent independent vaccines, which cause specific cellular and humoral immune response. In the assembled form, the combiHiVvac vaccine is a particle 40 to 100 nanometers in diameter, approaching in size to the HIV-1 virus.

The antibodies, which are formed by immunized mice under the action of vaccine, recognize the real HIV-1 proteins and neutralize the virus. This was shown by the experiments on the cell culture infected by the virus and processed by mice’s antibodies. Preclinical trial findings allow to hope that the combiHIVvac vaccine will fight efficiently even against modified HIV-1 variants.

The new vaccine is nontoxic. Its single injection to mice even in the fivefold dose does not cause derangements to the organs, and repeated injections reinforce inflammatory processes in the liver, but only in the case if the liver is already out of order. The combiHIVvac vaccine does not cause autoimmune diseases or anaphylactic reactions, it does not weaken the organism’s tolerance to infections either.

The scientists emphasize that as the combiHIVvac vaccine not only stimulates antibody production but also destroys the cells infected by the virus, this vaccine can be considered not only a prophylactic one but also as a therapeutic one. In the Novosibirsk researchers’ opinion, the vaccine they developed is ready for clinical trials.

Nadezda Markina | alfa
Further information:
http://www.informnauka.ru

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>